Houston TX B细胞淋巴瘤临床试验
16项针对 B细胞淋巴瘤的研究正在 Houston及周边约 30 英里内的站点招募参与者。打开研究详情可查看入选标准及联系研究团队的方式。
官方研究文本（英文）
正在为研究招募参与者？将此页面置顶展示 — $99 / 30天 →
A Phase 1 Study of JV-213 Autologous CD79b-targeting Chimeric Antigen Receptor T-cell Therapy in Adults With Relapsed or Refractory B-cell Lymphomas
招募中1 期
- The University of Texas M D Anderson Cancer Center, Houston
A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
招募中1 期
- MD Anderson Cancer Center, Houston
A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
招募中3 期
- MD Anderson Cancer Center, Houston
Trial of ONC-PluReceptor NK Cells With Epcoritamab and Tafasitamab for Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma
招募中1/2 期
- The University of Texas M. D. Anderson Cancer Center, Houston
A Study of Axicabtagene Ciloleucel and Glofitamab as Second-Line Therapy for Relapsed or Refractory Patients With Large B Cell Lymphoma
招募中2 期
- MD Anderson Cancer Center, Houston
A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)
招募中3 期
- Md Anderson Cancer Center, Houston
Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
招募中观察性研究
- Texas Children's Hospital, Houston
A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies
招募中1/2 期
- Research Site, Houston
Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL
招募中2 期
- Research Site, Houston
A Phase II Trial of Mosunetuzumab, Polatuzumab, Tafasitamab, and Lenalidomide in Patients With Relapsed B-cell NHL
招募中2 期
- M D Anderson Cancer Center, Houston
A Study to Investigate Safety and Effectiveness of Tacabrutideg (BGB-16673) in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies
招募中1/2 期
- The University of Texas Md Anderson Cancer Center, Houston
A Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma.
招募中1 期
- Clinical Trial Site, Houston
Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances
招募中1/2 期
- M D Anderson Cancer Center, Houston
DALY II USA/ MB-CART2019.1 for DLBCL
招募中2 期
- The University of Texas MD Anderson Cancer Center, Houston
Phase 1 Trial of BTM-3566 in Relapsed/Refractory Mature B Cell Lymphomas
招募中1 期
- MD Anderson Cancer Center, Houston
Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
招募中1 期
- Texas Children's Hospital/Baylor College of Medicine, Houston
其他城市的 B细胞淋巴瘤试验
- New York City, NY17 项研究
- Chicago, IL13 项研究
- Nashville, TN12 项研究
- Philadelphia, PA11 项研究
- Rochester, MN10 项研究
- Milwaukee, WI10 项研究
- Boston, MA10 项研究
- Baldwin Park, CA9 项研究
- Cleveland, OH8 项研究
- Salt Lake City, UT8 项研究
- Seattle, WA8 项研究
- Pittsburgh, PA7 项研究
Houston的其他研究
- 非小细胞肺癌143 项研究
- 乳腺癌126 项研究
- 癌症（所有类型）124 项研究
- 结直肠癌101 项研究
- 转移性癌症100 项研究
- 卵巢癌90 项研究
- 急性髓系白血病88 项研究
- 肺癌78 项研究
- 前列腺癌73 项研究
- 子宫内膜癌69 项研究
- 黑色素瘤61 项研究
- 胰腺癌59 项研究
数据来自 ClinicalTrials.gov，检索日期：2026年11月15日。每项研究自行设定入选标准，由研究团队决定谁能参与。